BRAF mutations in advanced cancers: clinical characteristics and outcomes

• Published in: PloS one 2011-10, Vol.6 (10), p.e25806-e25806
• Main Authors: El-Osta, Hazem, Falchook, Gerald, Tsimberidou, Apostolia, Hong, David, Naing, Aung, Kim, Kevin, Wen, Sijin, Janku, Filip, Kurzrock, Razelle
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Biology; Biopsy; Brain; Brain cancer; Cancer; Cancer metastasis; Cancer patients; Cancer therapies; Chemotherapy; Clinical trials; Codons; Colorectal cancer; Colorectal carcinoma; Consortia; Dehydrogenases; Development and progression; Diagnosis; Esophageal cancer; Esophagus; Extracellular signal-regulated kinase; Female; Gene mutation; Genetic aspects; Histology; Humans; Kinases; Laboratories; Lungs; Magnetic Resonance Imaging; Male; Medical diagnosis; Medical prognosis; Medicine; Melanoma; Metastases; Metastasis; Middle Aged; Multivariate analysis; Mutation; Neoplasms - genetics; Neoplasms - pathology; NMR; Nuclear magnetic resonance; Pathology; Patient outcomes; Patients; Proto-Oncogene Proteins B-raf - genetics; Raf protein; Signaling; Statistical analysis; Subgroups; Survival; Survival Analysis; Thyroid; Thyroid cancer; Tomography, X-Ray Computed; Tumorigenesis; Tumors; Young Adult
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0025806

Oncogenic BRAF mutations have been found in diverse malignancies and activate RAF/MEK/ERK signaling, a critical pathway of tumorigenesis. We examined the clinical characteristics and outcomes of patients with mutant (mut) BRAF advanced cancer referred to phase 1 clinic. We reviewed the records of 80 consecutive patients with mutBRAF advanced malignancies and 149 with wild-type (wt) BRAF (matched by tumor type) referred to the Clinical Center for Targeted Therapy and analyzed their outcome. Of 80 patients with mutBRAF advanced cancer, 56 had melanoma, 10 colorectal, 11 papillary thyroid, 2 ovarian and 1 esophageal cancer. Mutations in codon 600 were found in 77 patients (62, V600E; 13, V600K; 1, V600R; 1, unreported). Multivariate analysis showed less soft tissue (Odds ratio (OR) = 0.39, 95%CI: 0.20-0.77, P = 0.007), lung (OR = 0.38, 95%CI: 0.19-0.73, p = 0.004) and retroperitoneal metastases (OR = 0.34, 95%CI: 0.13-0.86, p = 0.024) and more brain metastases (OR = 2.05, 95%CI: 1.02-4.11, P = 0.043) in patients with mutBRAF versus wtBRAF. Comparing to the corresponding wtBRAF, mutBRAF melanoma patients had insignificant trend to longer median survival from diagnosis (131 vs. 78 months, p = 0.14), while mutBRAF colorectal cancer patients had an insignificant trend to shorter median survival from diagnosis (48 vs. 53 months, p = 0.22). In melanoma, V600K mutations in comparison to other BRAF mutations were associated with more frequent brain (75% vs. 36.3%, p = 0.02) and lung metastases (91.6% vs. 47.7%, p = 0.007), and shorter time from diagnosis to metastasis and to death (19 vs. 53 months, p = 0.046 and 78 vs. 322 months, p = 0.024 respectively). Treatment with RAF/MEK targeting agents (Hazard ratio (HR) = 0.16, 95%CI: 0.03-0.89, p = 0.037) and any decrease in tumor size after referral (HR = 0.07, 95%CI: 0.015-0.35, p = 0.001) correlated with longer survival in mutBRAF patients. BRAF appears to be a druggable mutation that also defines subgroups of patients with phenotypic overlap, albeit with differences that correlate with histology or site of mutation.